Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | Hormones and Cancer (Editorial Board)

We’re working on a new version of this journal site - preview it now
Hormones and Cancer

Hormones and Cancer

Editor-in-Chief: CAROL LANGE, PH.D.

ISSN: 1868-8497 (print version)
ISSN: 1868-8500 (electronic version)

Journal no. 12672

80,33 € Personal Rate e-only
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 6 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

EDITOR-IN-CHIEF

Carol Lange, PhD, University of Minnesota, Minneapolis, MN, USA

 

ASSOCIATE EDITORS

Seema Khan, MD, Northwestern University, Chicago, IL, USA

Jennifer K. Richer, PhD, University of Colorado, Anschutz, CO, USA

Tobias Else, MD, University of Michigan, Ann Arbor, MI, USA

 

EDITORIAL BOARD

Guillaue Assie, MD, PhD, Inst. National de la Santé et de la Recherche Médicale, Paris, France

Andrea Morandi, PhD, University of Florence, Florence, Italy

Steven P. Balk, MD, PhD, Beth Isreal Deaconess Medical Center, Boston, MA, USA

Eric Baudin, MD, PhD, Gustave Roussy Institute, Villejuif, France

Jason Carroll, PhD, Cancer Research UK Cambridge Institute, United Kingdom

Sheue-yann Cheng, PhD, National Cancer Institute, Bethesda, MD, USA

Paul J. Davis, MD, Albany Medical College, Albany, NY, USA

Scott M. Dehm, PhD, University of Minnesota, Minneapolis, MN, USA

Graeme Eisenhofer, PhD, The Technical University of Dresden, Dresden, Germany

Patricia V. Elizalde, PhD, IBYME, CONICET, Argentina

Martin Fassnacht, University of Wuerzburg, Germany

Lauren M. Fishbein, MD, University of Pennsylvania, Philadelphia, PA, USA

Jonna Frasor, PhD, University of Illinois, Chicago, IL, USA

Matthew P. Goetz, MD, Mayo Clinic, Rochester, MN, USA

Radhika Gogoi, MD, PhD, Geisinger Medical Center, Danville, PA, USA

Shannon Hawkins, MD, PhD, Indiana University, Indianapolis, IN, USA

Stephen G. Hillier, PhD, University of Edinburgh, Scotland

Shuk-mei Ho, PhD, University of Cincinnati, OH, USA

Michael W. Kilgore, PhD, University of Kentucky, Lexington, KY, USA

Kimberly K. Leslie, MD, University of Iowa, Iowa City, IA, USA

Ellis R. Levin, MD, University of California – Irvine, CA, USA

Donald P. McDonnell, PhD, Duke University Medical Center, Durham, NC, USA

Leigh C. Murphy, PhD, University of Manitoba, Winnipeg, MB, Canada

Steffi Oesterreich, PhD, University of Pittsburgh, PA, USA

Rosemary O'Connor, PhD, University College Cork, Ireland

Gail S. Prins, PhD, University of Illinois, Chicago, IL, USA

Gail P. Risbridger, PhD, Monash University, Victoria, Australia

Carol A. Sartorius, PhD, University of Colorado – Denver, CO, USA

Rebecca E. Schweppe, PhD, University of Colorado – Denver, CO, USA

Manisha Shah, MD, Ohio State University, Columbus, OH, USA

Hari Singhal, PhD, Roche Molecular Systems, Pleasanton, CA, USA

Julie Ann Sosa, MD, Duke University, Durham, NC, USA

Arun Sreekumarm, PhD, Baylor College of Medicine, Houston, TX, USA

Carlos Telleria, PhD, McGill University, Montreal, QC, Canada

Rajesh V. Thakker, MD, University of Oxford, United Kingdom

Nancy L. Weigel, PhD, Baylor College of Medicine, Houston, TX, USA

Siyuan Zheng, PhD, UT Health San Antonio, TX, USA

Douglas Yee, MD, University of Minnesota, Minneapolis, MN, USA

Christopher Li, MD, University of Washington, Seattle, WA, USA

Adrian Lee, PhD, University of Pittsburgh, Pittsburgh, PA, USA

Gary Hammer, MD, University of Michigan, Ann Arbor, MI, USA

Haihua Gu, PhD, Wenzhou Medical University, Wenzhou, China

Meet the Editor-in-Chief: 

Carol A. Lange

P_Carol-Lange-headshot_95x120px
Carol A. Lange, Ph.D. is the Tickle Family Land Grant Endowed Chair of Breast Cancer Research and Professor of Medicine and Pharmacology at the University of Minnesota Masonic Cancer Center (MCC) in Minneapolis, Minnesota, where she serves as Director of the Cancer Biology Training (NIH/NCI T32) Program and Co-Leader of the Cellular Mechanisms of Cancer Program within the MCC. Her research is focused on steroid hormone receptor action and signal transduction in breast and ovarian cancer. Her lab studies mechanisms of gene regulation by cross talk between growth factor-mediated signaling pathways and steroid hormone receptors, using the human progesterone receptor (PR) as an understudied model receptor that is highly relevant to ER+ women’s cancer and stem cell biology. Additional research focus is aimed at targeting stress-activated signaling pathways (p38 MAPKs, ERK5, HIFs, cortisol and glucocorticoid receptors (GR)) as inputs to GR-target gene expression. A key phospho-GR target gene discovered in the Lange lab, known as breast tumor kinase (Brk/PTK6), drives advanced breast and ovarian cancer progression (invasion, metastasis, changes in cancer stem cell biology).

Meet the Associate Editors 

Tobias Else

P_A56406_Tobias_95x120px
Dr. Else’s primary appointment is with the Division of Metabolism, Endocrinology and Diabetes at the University of Michigan. He received his MD degree from the University of Hamburg, Germany. He pursued his clinical training at the University of Hamburg (Residency: Internal Medicine) and the University of Michigan (Residency: Internal Medicine, Fellowship: Endocrinology). Dr. Else’s clinical practice focuses on the care for patients with benign and malignant endocrine tumors, particularly pheochromocytoma, adrenocortical tumors and neuroendocrine tumors as well as accompanying hormone excess syndromes. Dr. Else has a particular interest in taking care of patients with hereditary syndromes that predispose to the development of endocrine tumors (e.g. Multiple Endocrine Neoplasia, Hereditary Paraganglioma Syndrome). He attends a Multidisciplinary Endocrine Oncology Clinic and a Cancer Genetics Clinic, which evaluates patients for hereditary syndromes and also facilitates regular exams and surveillance for patients at risk for endocrine tumors. His academic and research interest is in translational sciences of primary aldosteronism, hereditary basis of endocrine tumors and in improvement of care for patients with these diagnoses.

Jennifer K. Richer

P_A56499_Richer_Jennifer_2016_95x120px
Dr. Jennifer K. Richer, Professor of Pathology, University of Colorado Anschutz Medical Campus, has over 25 years of experience in the field of steroid hormone receptor action. Her research program centers on the function of estrogen, progesterone and androgen receptors in breast, endometrial and ovarian cancer. Recent work identified unique roles for the androgen receptor in the various subtypes of breast cancer. Another laboratory focus is on non-coding RNA that affect hormone receptor action, immune recognition and tumor progression. Dr. Richer has served on numerous Endocrine Society and American Association for Cancer Research committees and was a co-organizer of the Keystone Symposium on Nuclear Receptors in 2016.

Seema Ahsan Khan

P_A56680_khan w lcc coat_95x120px
Dr. Seema Ahsan Khan, MD, SM, is a surgical oncologist and clinician scientist working in cancer prevention and the identification of novel molecular biomarkers of breast cancer risk, including steroid hormones in breast tissue and nipple fluid. Dr. Khan has considerable expertise in the conduct of early phase prevention trials with biomarker endpoints, ranging from soy isoflavone supplementation in healthy women who are considered to be at high risk for breast cancer development to anti-progesterone compounds and 4-hydroxytamoxifen in the pre-surgical window setting. She has pioneered the use of novel transdermal delivery methods for breast cancer chemoprevention agents. Dr. Khan’s expertise will facilitate seamless review of our pre-clinical and clinical submissions.

Read this Journal on Springerlink

For authors and editors


  • Journal Citation Reports®
    2018 Impact Factor
  • 2.239
  • Aims and Scope

    Aims and Scope

    Close

    Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science,  pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research.  In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.

    Hormones and Cancer publishes 6 times per year with print issues mailing in February, April, June, August, October, and December. 

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Statement of Principle

    Statement of Principle

    Close

  • Instructions for Authors

    Instructions for Authors

    Close

  • Author Academy: Training for Authors
  • Author Services
  • Copyright Information

    Copyright Information

    Close

    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.


    © Springer Science+Business Media New York

Alerts for this journal

 

Get the table of contents of every new issue published in Hormones and Cancer.